Dual Mechanisms for APOBEC3 Suppression by HIV-1 Vif
HIV-1 Vif 抑制 APOBEC3 的双重机制
基本信息
- 批准号:9133101
- 负责人:
- 金额:$ 3.11万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2015
- 资助国家:美国
- 起止时间:2015-08-01 至 2017-07-31
- 项目状态:已结题
- 来源:
- 关键词:Antiviral AgentsAntiviral TherapyBindingBiochemical GeneticsCD4 Positive T LymphocytesCell LineCell physiologyCellsChIP-seqComplexCouplesDNA BindingDataDimerizationDown-RegulationEnzymesFellowshipGene ExpressionGenesGenetic TranscriptionGenetic studyHIV-1HomeostasisHumanImmuneIn Situ HybridizationInfectionKnock-outLightMacaca mulattaMediatingMessenger RNAModelingOutcomePathogenesisPathway interactionsPolyubiquitinationPrimary InfectionProcessProteinsRUNX1 geneRationalizationRegulationSIVSiteSubfamily lentivirinaeSurfaceT-Cell DevelopmentT-LymphocyteTestingTissuesTonsillar TissueTranscriptional RegulationViralViral PathogenesisVirus ReplicationWorkbonecofactorimmune functionin vivoknock-downnoveloverexpressionpreventprotein degradationpublic health relevanceresearch studytranscription factorubiquitin ligaseubiquitin-protein ligase
项目摘要
DESCRIPTION (provided by applicant): HIV-1 and nearly all other lentiviruses encode an accessory protein termed viral infectivity factor (Vif) that is required for productive viral replication and pathogenesis in vivo. Vif functions canonically to overcome restriction by the cellular APOBEC3 (A3) proteins by triggering their polyubiquitination and degradation through an E3 ubiquitin ligase complex. We recently identified the transcription factor CBFß as a Vif cofactor required for the assembly and function of this E3 ubiquitin ligase complex. CBFß is expressed in CD4+ T cells and functions by heterodimerizing with the DNA binding RUNX transcription factors to regulate expression of genes involved in T cell development and immune function. My preliminary knockdown and knockout experiments indicate that CBFß is a positive regulator of A3 transcription in T cells. Ablating CBFß function suppresses A3 gene transcription and causes a concomitant increase in Vif-deficient HIV-1 infectivity. I hypothesize that CBFß/RUNX complexes directly stimulate A3 gene transcription and that Vif disrupts this process by hijacking CBFß to form the Vif/CBFß E3 ubiquitin ligase complex that degrades A3 proteins. Thus, Vif efficiently couples two independent and highly complementary mechanisms to suppress A3 antiviral activity. The studies proposed here will test this potentially paradigm-shifting hypothesis, and could provide an elegant evolutionary rationalization for why Vif hijacks CBFß as opposed to any other cellular protein.
描述(由申请人提供):HIV-1和几乎所有其他慢病毒编码一种称为病毒感染因子(Vif)的辅助蛋白,该蛋白是体内病毒复制和致病所必需的。Vif的典型功能是通过E3泛素连接酶复合物触发细胞APOBEC 3(A3)蛋白的多聚泛素化和降解来克服其限制。我们最近确定了转录因子CBF 3作为一个Vif辅因子所需的装配和功能的E3泛素连接酶复合物。CBF在CD 4 + T细胞中表达,并通过与DNA结合RUNX转录因子异二聚化来调节参与T细胞发育和免疫功能的基因的表达。我的初步敲除和敲除实验表明,CBF β是T细胞中A3转录的正调节因子。抑制CBF 3功能抑制A3基因转录并导致Vif缺陷型HIV-1感染性的伴随增加。我假设CBF 3/RUNX复合物直接刺激A3基因转录,Vif通过劫持CBF 3形成Vif/CBF 3 E3泛素连接酶复合物降解A3蛋白来破坏这一过程。因此,Vif有效地将两种独立且高度互补的机制偶联以抑制A3抗病毒活性。这里提出的研究将测试这一潜在的范式转变假设,并可以为为什么Vif劫持CBF 3而不是任何其他细胞蛋白质提供一个优雅的进化合理化。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Brett D Anderson其他文献
Author Correction: Sustained perfusion of revascularized bioengineered livers heterotopically transplanted into immunosuppressed pigs
作者更正:异位移植到免疫抑制猪体内的血运重建生物工程肝脏的持续灌注
- DOI:
10.1038/s41551-019-0483-3 - 发表时间:
2019 - 期刊:
- 影响因子:28.1
- 作者:
Mohammed F. Shaheen;D. Joo;J. Ross;Brett D Anderson;Harvey S. Chen;R. Huebert;Yi Li;B. Amiot;Anne Young;Viviana Zlochiver;Erek D. Nelson;T. Mounajjed;A. Dietz;G. Michalak;Benjamin G. Steiner;Dominique S. Davidow;Christopher R. Paradise;A. V. van Wijnen;V. Shah;Mengfei Liu;S. Nyberg - 通讯作者:
S. Nyberg
Brett D Anderson的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Brett D Anderson', 18)}}的其他基金
Dual Mechanisms for APOBEC3 Suppression by HIV-1 Vif
HIV-1 Vif 抑制 APOBEC3 的双重机制
- 批准号:
8921349 - 财政年份:2015
- 资助金额:
$ 3.11万 - 项目类别:
相似海外基金
Dose Flexible Combination 3D-Printed Delivery Systems for Antiviral Therapy in Children
用于儿童抗病毒治疗的剂量灵活组合 3D 打印输送系统
- 批准号:
10682185 - 财政年份:2023
- 资助金额:
$ 3.11万 - 项目类别:
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
475843 - 财政年份:2022
- 资助金额:
$ 3.11万 - 项目类别:
Studentship Programs
COVID-19 Immunologic Antiviral therapy with Omalizumab (CIAO trial) - An Adaptive Phase II Randomized-Controlled Clinical Trial
使用奥马珠单抗进行 COVID-19 免疫抗病毒治疗(CIAO 试验)——适应性 II 期随机对照临床试验
- 批准号:
474485 - 财政年份:2022
- 资助金额:
$ 3.11万 - 项目类别:
Studentship Programs
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10481430 - 财政年份:2022
- 资助金额:
$ 3.11万 - 项目类别:
Discovery of Bunyaviral Endonuclease Inhibitors for Antiviral Therapy
用于抗病毒治疗的布尼亚病毒核酸内切酶抑制剂的发现
- 批准号:
10683329 - 财政年份:2022
- 资助金额:
$ 3.11万 - 项目类别:
An interdisciplinary approach towards antiviral therapy discovery
抗病毒疗法发现的跨学科方法
- 批准号:
nhmrc : 1196520 - 财政年份:2021
- 资助金额:
$ 3.11万 - 项目类别:
Investigator Grants
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10260234 - 财政年份:2021
- 资助金额:
$ 3.11万 - 项目类别:
Applying an 'omics' approach to predict hepatic decompensation events and hepatocellular carcinoma in veterans after HCV cure with direct acting antiviral therapy
应用“组学”方法预测退伍军人在使用直接作用抗病毒疗法治愈 HCV 后的肝失代偿事件和肝细胞癌
- 批准号:
10548114 - 财政年份:2021
- 资助金额:
$ 3.11万 - 项目类别:
Disparities in the Diffusion of Direct-Acting Antiviral Therapy for Hepatitis C among Baby Boomers: A Mixed-Methods Study
婴儿潮一代丙型肝炎直接作用抗病毒疗法传播的差异:一项混合方法研究
- 批准号:
10400318 - 财政年份:2020
- 资助金额:
$ 3.11万 - 项目类别:
Development of novel antiviral therapy targeting hepatitis B virus host restriction factor
针对乙型肝炎病毒宿主限制因子的新型抗病毒疗法的开发
- 批准号:
20K08371 - 财政年份:2020
- 资助金额:
$ 3.11万 - 项目类别:
Grant-in-Aid for Scientific Research (C)